



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## Application of

Applicant(s)

: GHOSHAL, et al.

Serial No.

: 10/622,254

Filed

: July 18, 2003

Title

: Ecstasy-Class Derivatives, Immunogens, and Antibodies and Their Use in

Detecting Ecstasy-Class Drugs

Docket

: RDID02024US

Art Unit

:1645

Customer No: 23690

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

"Express Mail" Label No. EV421106229US

toher 20

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of person mailing paper or fee

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.56, 1.97 & 1.98

Applicants submit herewith patents, publications, and other information of which he is they are aware, which they believe may be material, as defined in 37 CFR §1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 CFR §1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 CFR §1.97(h), constitute an admission that any patent, publication, or other information referred to is, or is considered to be, material to the patentability of this invention. No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 & 103, and Applicants reserve the right, pursuant to 37 CFR §1.131 or otherwise, to establish otherwise. Further, pursuant to 37 CFR §1.97(g), the filing of this Statement should not be construed as a statement that a search has been made or that no other material information exists.

This Information Disclosure Statement is being filed within the period set forth in 37

CFR §1.97(b) because it is believed to be filed before the mailing date of a first office action on

the merits.

The Office has waived the requirement pursuant to 37 CFR §1.98(a)(2)(i) for submitting

a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national

patent applications filed after June 30, 2003 and for all international applications that have

entered the national stage under 35 USC §371 after June 30, 2003. Therefore, no copies of each

cited U.S. patent and each cited U.S. patent application publication are enclosed, but the cited

U.S. patents and the cited U.S. patent application publications are listed on PTO/SB/08A.

No additional fees are believed to be necessary, however, should any fees be deemed

required, the Commissioner is authorized to charge such fees to Deposit Account 02-2958, but is

not to include any payment of issue fees.

Respectfully submitted,

ROCHE DIAGNOSTICS OPERATIONS, INC.

**3**17

Marilyn L. Amick

Registration No. 30,444

9115 Hague Road, P.O. Box 50416

Indianapolis, IN 46250-0416 Telephone: (317) 521-7561

Facsimile: (317) 521-2883

Encls.

-2-

INFORMATION DISCLOSURE				Docket Number (Optional)   RDID 02024 US				Application Number 10/622,254		
O'' E SITATION								10,022,201		
(Use several sheets if necessary)				Applicants(s) Ghoshal et al						
الله الله			<del></del>				Group Art Unit: 164	Group Art Unit: 1645		
Examiner	O EMARY	7		ii s	PATENT DO	CHENTS	•			
Examiner Initials	Ref	Document Number		Date		Name	Class	s Subclass	Filing Date (If Appropriate)	
·	<del></del>	4,041,076	8/9/1977		Avenia e	t al.	260	559		
		5,470,997	11/28/1995		Buechler		558	254		
	-									
	<u> </u>									
	<del> </del>									
							+			
	<del> </del>						+			
									<u> </u>	
Ref Document Number			FOREIGN PATENT DOCUMENTS  Date Country Class				s Subclass Translation			
	1441	2 oouthest ( value)		<u> </u>		country	Cias	Subciass	Translation	
				,						
		Other Do	cume	nts (Includ	ing Author.	Title, Date. Perti	nent Page	es. Etc.)		
		Other Documents (Including Author, Title, Date, Pertinent Pages, Etc.)  Hadri, A. El et al., "Synthesis and bovine Beta3-adrenergic agonistic activities of a novel series of								
		aryloxypropanolamines," Pharmazie, Vol. 56, No. 7, 2001, pp. 517-522								
				<u></u>						
<del></del>					<del></del>					
Examiner						Date Considered				
EXAMINE	R: Initia	l if citation considered, whether	or not	citation is in c	onformance wit	h MPEP Section 60	9; Draw line	e through citation if no	t in conformance and not	
considered. Include copy of this form with next communication to applicant.										